Key clinical point: Adults with inflammatory bowel disease were less likely to discontinue vedolizumab, compared with adalimumab, golimumab, or infliximab over 3 years.

Major finding: After 3 years, the risk of therapy discontinuation was significantly lower for vedolizumab patients, compared with adalimumab and golimumab (hazard ratios 0.86 and 0.60, respectively).

Study details: The data come from a retrospective study of 15,984 adults aged 18 years and older who were treatment naive to biologics.

Disclosures: The study received no outside funding. Lead author Dr. Helwig disclosed lecture and consulting fees from AbbVie, Amgen, Biogen, Celltrion, Hexal, MSD, Ferring, Falk Foundation, Takeda, Mundipharma, Pfizer, Hospira, and Vifor Pharma. Dr. Isaacs disclosed serving on the Data and Safety Monitoring Board (DSMB) for Janssen.